After obtaining his degree in Biochemistry and Applied Clinical Biochemistry from UMIST in 2001, Andrew completed a PhD in Molecular Parasitology from the University of Manchester, studying the folate biosynthetic pathway of the malaria parasite Plasmodium falciparum. In 2006 he joined the Sinden lab at Imperial College, London, to study the sexual stages of Plasmodium, with an emphasis on developing transmission-blocking interventions (TBIs) to target the parasite within the mosquito host, inhibiting or preventing the onward transmission of malaria. He is currently a Principal Investigator in the DoLS, and his main interests focus on the identification of novel anti-malarial transmission blocking vaccine targets, vaccine delivery, the development of assays to examine TBI efficacy, and assessing the practical impact of introducing TBIs on populations of mosquitoes and vertebrate in both the laboratory and the field.
Angrisano F, Blagborough AM, 2018, Understanding Human-Derived Antibodies Generated by Polymorphic Malaria Vaccine Against Merozoite Surface Protein 2., J Infect Dis, Vol:218, Pages:5-6
et al., 2018, Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density, Elife, Vol:7, ISSN:2050-084X
et al., 2018, Detection of malaria sporozoites expelled during mosquito sugar feeding, Scientific Reports, Vol:8, ISSN:2045-2322
et al., 2018, Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model, Scientific Reports, Vol:8, ISSN:2045-2322
et al., 2018, Immunization with Transgenic Rodent Malaria Parasites Expressing Pfs25 Induces Potent Transmission-Blocking Activity, Scientific Reports, Vol:8, ISSN:2045-2322